ENDV Stock Overview
A biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Endonovo Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0015 |
| 52 Week High | US$0.017 |
| 52 Week Low | US$0.0007 |
| Beta | -0.43 |
| 11 Month Change | 15.38% |
| 3 Month Change | -51.61% |
| 1 Year Change | -89.86% |
| 33 Year Change | -95.73% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| ENDV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 87.5% | -0.009% | 0.5% |
| 1Y | -89.9% | 9.8% | 23.9% |
Return vs Industry: ENDV underperformed the US Biotechs industry which returned 9.8% over the past year.
Return vs Market: ENDV underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| ENDV volatility | |
|---|---|
| ENDV Average Weekly Movement | 38.7% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: ENDV's share price has been volatile over the past 3 months.
Volatility Over Time: ENDV's weekly volatility (39%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | n/a | Alan Collier | www.endonovo.com |
Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis.
Endonovo Therapeutics, Inc. Fundamentals Summary
| ENDV fundamental statistics | |
|---|---|
| Market cap | US$595.24k |
| Earnings (TTM) | -US$4.40m |
| Revenue (TTM) | US$255.72k |
2.3x
P/S Ratio-0.1x
P/E RatioIs ENDV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ENDV income statement (TTM) | |
|---|---|
| Revenue | US$255.72k |
| Cost of Revenue | US$9.69k |
| Gross Profit | US$246.03k |
| Other Expenses | US$4.65m |
| Earnings | -US$4.40m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.011 |
| Gross Margin | 96.21% |
| Net Profit Margin | -1,722.23% |
| Debt/Equity Ratio | -30.7% |
How did ENDV perform over the long term?
See historical performance and comparison